Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Eun-Sil Sung"'
Autor:
Yong-Sung Kim, Young-Don Lee, Seok-Ki Kim, Se-Ho Kim, Ki-Su Kim, Ye-Jin Kim, Eun-Sil Sung, Tae-Hwan Shin
The limited localization and penetration of monoclonal antibodies (mAb) into solid tumors restricts their antitumor efficacy. Here, we describe a solid tumor–targeting antibody with enhanced tumor penetration activity. We designed a 22-residue pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12243c9ef53911611147f460baca63f3
https://doi.org/10.1158/1535-7163.c.6536395.v1
https://doi.org/10.1158/1535-7163.c.6536395.v1
Autor:
Yong-Sung Kim, Young-Don Lee, Seok-Ki Kim, Se-Ho Kim, Ki-Su Kim, Ye-Jin Kim, Eun-Sil Sung, Tae-Hwan Shin
PDF - 2613K, Figure S1: Structural analysis of NRP1, NRP2, and Sema3A, and their interactions to facilitate the understanding of the interactions between Sema3A and NRP1/2. Figure S2: SDS-PAGE analyses of the purified proteins showing that NRP1/2-b1b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3482a3d96836baca0b67456108a687af
https://doi.org/10.1158/1535-7163.22500220.v1
https://doi.org/10.1158/1535-7163.22500220.v1
Autor:
Yong-Sung Kim, Myung-Hee Kwon, Won-Jae Kwag, Yoo-Hoi Park, Sang-Koo Park, Yoon-Seon Jang, Seung-Hyun Lee, Kyung-Jin Park, Eun-Sil Sung
Supplementary Data from A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a536af59e35e2ee1e1ed43983858128c
https://doi.org/10.1158/1535-7163.22484475.v1
https://doi.org/10.1158/1535-7163.22484475.v1
Autor:
Yong-Sung Kim, Myung-Hee Kwon, Won-Jae Kwag, Yoo-Hoi Park, Sang-Koo Park, Yoon-Seon Jang, Seung-Hyun Lee, Kyung-Jin Park, Eun-Sil Sung
The proapoptotic tumor necrosis factor–related apoptosis inducing ligand (TRAIL) receptors death receptor (DR) 4 and DR5 are attractive targets to develop the receptor-specific agonistic monoclonal antibodies (mAb) as anticancer agents because of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e3e2d972c1295a98173d1a98b192b9d
https://doi.org/10.1158/1535-7163.c.6531423.v1
https://doi.org/10.1158/1535-7163.c.6531423.v1
Autor:
Eom Jaehyun, Ahn Jinhyung, Eun-Sil Sung, An Sungwon, Kim Dongin, Yoo Jiseon, Weon-Kyoo You, Jung Jinwon, Hyesu Yun, Lee Bora, Han-Byul Lee, Sung Byungje, Sehyun Kim, Song Daehae, Jeonghun Lee, Danica Stanimirovic, Jung-Won Shin, Sungho Maeng, SuYeon Lee, Jagdeep K. Sandhu, Donghwan Kim, Arsalan S. Haqqani, Pak Youngdon, Sang-Hoon Lee, Son Yonggyu
Publikováno v:
SSRN Electronic Journal.
Delivering effective therapeutics to the brain is a great challenge. Molecular shuttles use receptors expressed on brain endothelial cells to deliver therapeutics. Currently, antibodies targeting transferrin receptor (TfR) have been widely developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de7fd8be7b6e2445dd312890a6baee6a
https://doi.org/10.2139/ssrn.3756523
https://doi.org/10.2139/ssrn.3756523
Autor:
Kyung Jin Lee, Bo-Eun Lee, Hyunejoo Kim, Eun-Sil Sung, Jongman Yoo, Chan Kwon Park, Jonghwa Won, Yoon Park, Jaeho Jung, Han-Byul Lee, Jihyo Kim, Eunyoung Park, Uijung Jung, Youngeun Hong, Minkyung Ko, Seung Joon Kim
Publikováno v:
Cancer Research. 81:1633-1633
PD-(L)1 blockade has demonstrated the remarkable success for cancer treatment, but significant unmet needs remain to fully achieve clinical benefit for PD-(L)1 resistant/refractory patients. Recent studies suggest that expression of Lymphocyte Activa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26c53c88402e06f954a561cdf7adffcd
https://doi.org/10.1158/1538-7445.am2021-1633
https://doi.org/10.1158/1538-7445.am2021-1633
Autor:
Minwoo Jeon, Han-Byul Lee, Seongju Jeong, Shin Hwang, Hyung-Don Kim, Zhengyi Wang, Hyunjoo Kim, Su-Hyung Park, Eun-Sil Sung, Jung Uijung, Jeon Jaehyoung, Eui-Cheol Shin, Yangmi Lim, Shinai Lee, Jiang Wenqing, Kim Youngkwang, Eunyoung Park, Youngeun Hong, Fang Lei, Son Yonggyu, Jonghwa Won, Jaeho Jung
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundStimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs. However, dose-dependent hepatotoxicity was observed i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdf732c97f8b66210eb71ae01eb2df5e
https://doi.org/10.1136/jitc-2021-002428
https://doi.org/10.1136/jitc-2021-002428
Autor:
Seok Ki Kim, Yong Sung Kim, Tae Hwan Shin, Ye-Jin Kim, Young-Don Lee, Eun-Sil Sung, Ki-Su Kim, Se-Ho Kim
Publikováno v:
Molecular Cancer Therapeutics. 13:651-661
The limited localization and penetration of monoclonal antibodies (mAb) into solid tumors restricts their antitumor efficacy. Here, we describe a solid tumor–targeting antibody with enhanced tumor penetration activity. We designed a 22-residue pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354f981b82582525411311f6c7f9c8df
https://doi.org/10.1158/1535-7163.mct-13-0748
https://doi.org/10.1158/1535-7163.mct-13-0748
Publikováno v:
Experimental Cell Research. 318:1564-1576
Head and neck squamous cell carcinoma (HNSCC) is often resistant to conventional chemotherapy and thus requires novel treatment regimens. Here, we investigated the effects of the proteasome inhibitor MG132 in combination with tumor necrosis factor-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52332b91e874c3a11d0fdf77afc1b73c
https://doi.org/10.1016/j.yexcr.2012.04.003
https://doi.org/10.1016/j.yexcr.2012.04.003